Background: Anti-silencing function 1B (ASF1B), a histone H3-H4 chaperone, is crucial for S-phase progression and cell proliferation. Recent studies have shown that ASF1B may be used as a new proliferation marker for cancer prognosis. However, the prognostic value and effect of ASF1B on tumor cells and the immune microenvironment in hepatocellular carcinoma (HCC) remain unclear.Methods: We analyzed the expression of ASF1B and its prognostic value using The Cancer Genome Atlas (TCGA) database (as a training set) and other databases, and we validated the findings by immunohistochemistry in our clinical database, containing 141 HCC patients . Gene set enrichment analysis (GSEA) and gene set variation analysis (GSVA) were performed to probe the tumor-associated biological processes of ASF1B in HCC. The interrelationships between ASF1B expression and tumor immunological characteristics were analyzed by multiple databases. The Imvigor210 cohort was retrieved to assess the ability of ASF1B to predict immunotherapy efficacy.Results: ASF1B was highly expressed in tumor tissue compared to paracancerous tissue. High ASF1B expression was associated with worse overall survival (OS) and progression-free survival (PFS) in the training set  and validation set . Multivariate analysis revealed that ASF1B was an independent prognostic factor associated with OS and PFS. GSEA and GSVA suggested that ASF1B was involved in tumor-associated biological processes, including the cell cycle, DNA replication, base excision repair, mismatch repair, RNA degradation, ubiquitin-mediated proteolysis, and nucleotide excision repair. Further analysis revealed that the levels of ASF1B were positively correlated with the immune cells infiltration of B cells, CD8+ T cells, CD4+ T cells, neutrophils, and dendritic cells. However, ASF1B was positively correlated with Treg cell infiltration and inhibitory immune checkpoints in exhausted T cells. Patients who received anti-PD-L1 immunotherapy with high ASF1B expression had a higher objective response.Conclusion: The ASF1B level is an independent prognostic factor and may serve as a potential immunotherapeutic target. Hepatocellular carcinoma (HCC), the major type of primary liver cancer, is estimated to be the fourth most common cause of cancer-related death, which exacts a heavy disease burden worldwide . China i+ FOXP3+ regulatory T cells (Tregs) and enhances CD8+ T cell activity (The tumor immune microenvironment (TIME) is a crucial factor for the progression of HCC and for the response to immunotherapy . Over thactivity . CDK7 inactivity . TherefoIn all eukaryotes, DNA and histones are precisely organized into chromatin, and assembly and disassembly processes are vital processes during the cell cycle. Histone chaperones are involved in all aspects of histone dynamics, particularly promoting specific chromatin assembly pathways throughout cellular life . Anti-siIn the present study, we systematically and comprehensively analyzed the expression of ASF1B from online public databases and our medical center’s databases and then assessed its correlation with clinicopathological factors and patients prognosis using data from The Cancer Genome Atlas database (TCGA) and the database from our center. We further explored the potential associations of ASF1B with tumor-infiltrating immune cells and the efficacy of immunotherapy using multiple online public databases.In total, 141 patients were enrolled from January 2013 to December 2015 as a validation set to validate the findings from public databases. Sixty-one of these patients had paired tumors and adjacent tissue samples. All patients in this cohort underwent R0 resection, and the pathological diagnosis was confirmed as HCC identified by the pathology department at the First Affiliated Hospital of Xi’an Jiaotong University . The patients’ primary characteristics are listed in Immunohistochemistry was performed as described previously . The ASF2 at 37°C. The human ASF1B-target small interfering (si)RNAs  were applied to construct ASF1B knockdown HCC lines. In this process Lipofectamine 2000  was used according to it’s protocol.Hep3B and Huh7 were a gift from JuSeog Lee . All cells were maintained in high glucose Dulbecco’s modified Eagle’s medium  with 10% FBS  and 100 U/ml penicillin and streptomycin. Cell lines were incubated with 95% humidified air and 5% COHCC cells  were seeded into 96-well plates. Relative cell numbers were quantified per day using the 3--2,5-diphenyltetrazolium bromide (MTT) assay. Absorbance was measured at 492 nm. For colony formation assays, HCC cells were seeded in the 6-well plates at a density of 500/well. After 14 days, Each group were fixed in 4% paraformaldehyde for 20 min and stained with 0.1% crystal violet solution for imaging and counting.At first, protein was extracted from LO2 normal liver cells and 5 HCC cell lines . Then Western blotting was operated in accordance with standard protocols. The following primary antibodies were applied: anti-β-actin antibody  and anti-ASF1B antibody . The ASF1B detection was repeated at least three times. The band intensities were measured using ImageJ .https://portal.gdc.cancer.gov/). Cases with insufficient or missing data were filtered out, and 371 patients data were adopted as a training set for survival analysis. We compared the overall survival (OS) and progression-free survival (PFS) of HCC patients divided by the ASF1B median expression value. The clinical characteristics of the included patients were summarized in Clinical information and transcriptomic data of 375 HCC patients and 49 adjacent cancer samples were downloaded from TCGA data portal (http://lifeome.net/database/hccdb) was used to explore ASF1B mRNA expression in HCC and adjacent noncarcinoma tissues. The HCCDB database contains 15 public datasets that cover 3,917 samples (The Integrative Molecular Database of Hepatocellular Carcinoma (HCCDB) database  and the mutant-allele tumor heterogeneity (MATH) score of tumor samples in the TCGA-LIHC dataset were also computed via the “maftools” package.p value of <0.05 and a FDR q-value of <0.25 were used as the cutoff criteria. In addition, GSVA was performed to further analyze the difference in pathways between the subtypes of ASF1B using the GSVA package  and gene set variation analysis (GSVA) were used to investigate the mechanisms of ASF1B in HCC . In the  package .https://cistrome.shinyapps.io/timer/) was used to analyze immune infiltration in HCC  and gene markers of infiltrating immune cells in HCC. Furthermore, other algorithms  were utilized to quantify the infiltrating immune cells and to verify the TIMER results.The tumor immune estimation resource (TIMER)  was utilized to calculated the infiltrating score of 16 immune cells and the activity of 13 immune-related pathways in the “gsva” R package , which ap < 0.05 was considered statistically significant. SPSS 24.0  was used to perform the statistical analyses.In this study, unpaired t test and one-way analysis of variance were used to calculate the comparison of continuous variables. The chi-square test was used to process the categorical variables. Kaplan-Meier survival curves was used to display the OS and PFS. Univariate and multivariate regression analyses were used to identify independent prognostic factors. The correlation between genes was detected with Pearson analysis. All the tests were two-sided, and A flowchart of this study is illustrated in To validate the above findings, HCC cancer tissues and corresponding adjacent tissues from 61 patients were tested by IHC. The protein expression of ASF1B in cancer tissues was higher than that in noncancerous tissues . Westernp < 0.001), males (p = 0.018), poorer differentiation (p < 0.001), higher levels of AFP (p < 0.001), more advanced T stage (p = 0.001), and TNM stage (p = 0.001). In the validation set, a high ASF1B protein level was correlated with poorer differentiation (p = 0.038), more advanced T stage (p = 0.013), and TNM stage (p = 0.002). The Kaplan-Meier survival curves revealed that patients with high ASF1B expression had poorer OS and PFS than patients with low ASF1B expression in the training set , M stage (p = 0.014), TNM stage (p < 0.001), and ASF1B expression (p < 0.001) as well as the association between PFS and T stage (p < 0.001), TNM stage (p < 0.001), and ASF1B expression (p < 0.001) in the training set (p = 0.014), tumor number (p = 0.024), vascular invasion (p = 0.018), T stage (p < 0.001), N stage (p = 0.033), TNM stage (p < 0.001), and ASF1B expression (p < 0.001). The factors significantly associated with PFS were tumor size (5 cm) (p = 0.001), vascular invasion (p = 0.046), T stage (p < 0.001), TNM stage (p < 0.001), and ASF1B expression (p < 0.001) in the validation set  and PFS  in the training set. In addition, the validation set verified that ASF1B expression was indeed an independent risk factor for patient prognosis   , 4D. Fur= 1.869) . Thus, tPrevious studies have reported that ASF1B functions as an oncogene to promote tumor growth by participating in the cell cycle . Given tp = 0.025).To explore the difference of genomics between the ASF1B-highand ASF1B-low subsets, we examined somatic mutation from the TCGA-LIHC datasets. Emerging preclinical and clinical evidence has revealed that blocking the tumor cell cycle not only inhibits the proliferation of cancer cells but also mediates a wide range of immunomodulatory effects that involve both malignant and nonmalignant components of the TIME, thereby suggesting novel immunotherapeutic avenues . Thus, w+ T cells, CD8+ T cells, B cells, macrophages, neutrophils, and dendritic cells (DCs) in HCC , CD4+ Th2 cells , and NK cells  infiltration. The QUANTISEQ results indicated that ASF1B was positively related to B cells , CD8+ T cells  and Treg cells  infiltration  in HCC . The xCeltration . Howeverltration . Comparer = 0.428, p = 9.06e-17), CTLA-4 , LAG3 , TIM-3 , and TIGIT . In addition, ASF1B also correlated with the CCR8, STAT5b, and TGFB1 gene markers in Tregs as well as the CD11b and CD15 gene markers in neutrophils. The above results suggested that ASF1B may indicate an immunosuppressive tumor microenvironment with increasing immune suppressive cells and dysfunctional and exhausted T cells even though it may cause increased T cell and other immune cells infiltration, which could influence the patient outcome in HCC. The hypothesis figure for the correlation between ASF1B expression and immune cell distribution is illustrated in To validate the above results, the correlation between ASF1B and the immune marker sets of immune cells in HCC was explored using the TIMER database. The correlation was adjusted for tumor purity, which influences the immune infiltration analysis. As shown in p = 0.076) (p < 0.001)  of the treatment response data of patients who underwent anti-PD-L1 immunotherapy was retrieved to assess the ability of ASF1B to predict immunotherapy efficacy . Kaplan-= 0.076) . A highe< 0.001) . These rIn the present study, by incorporating data from a public databases and our tumor center, we found that ASF1B expression was higher in tumor tissue compared to paracancerous normal tissues and that the high expression of ASF1B predicted poor outcome in HCC patients. Further systematic and comprehensive analysis of public databases revealed that ASF1B was also correlated with immune cell infiltration and activation in the tumor microenvironment of HCC and that it could predict the efficacy of immunotherapy.The histone H3-H4 chaperone, ASF1, is a key factor for S-phase progression in the cell cycle in various organisms . Previou+ immune cells, CD3+ T cells, and activated dendritic cells (+ T cells, CD8+ T cells, B cells, neutrophils, macrophages, and DCs in HCC which was also confirmed by Zhan’s study. Furthermore, we explored the correlations of ASF1B expression with genetic markers of various immune cells after tumor purity adjusting. The results were in line with the above findings and showed that ASF1B expression was correlated with most immune cell markers in HCC. + T cells and CD8+ T cells, infiltrating T cells in the tumor microenvironment are inactivated and exhausted. In addition, although TMB was not different between the ASF1B-high group and -low group, MATH analysis revealed that the high ASF1B expression exhibited higher abundances of tumor heterogeneity, which is generally associated with impaired immunity in multiple malignances (Cell cycle dysregulation and immune escape are hallmarks of malignant tumors . Althougic cells . It has ic cells . Thus, aic cells . ASF1B eignances . Consideignances . We founignances . And theignances . In addiignances . Exosomeignances . Tumor mignances . How ASFin vivo and vitro to investigate how the aberrant elevation of ASF1B influences tumor behavior and the TIME in HCC. Second, the clinical data on immunotherapy administered to patients with HCC were unclear, which prevented us from performing a more detailed analysis. Thus, more clinical information needs to be collected on HCC patients applying immunotherapy to confirm these results.Third, integrating genomic, transcriptomic, proteomic, metabolomic and epigenomic datasets via multi-omics analysis could derive a deeper understanding of the development and progression of cancer (The present study systematically reported the clinical significance of ASF1B and its effect on the TIME in HCC, but it also had several limitations. First, although we included data from our center to validate the expression and prognostic value of ASF1B, our results present limited evidence about the mechanism by which ASF1B upregulation affects the outcome of patients and the TIME with HCC. But we are currently conducting basic experiments f cancer . More muIn summary, this study revealed that the expression of ASF1B was elevated in HCC tissues, and it could be a potential biomarker to predict HCC patient prognosis. In addition, high ASF1B expression is related to immunosuppressive tumor microenvironment characteristics with high expression of T cell exhaustive markers in HCC. However, high ASF1B expression predicts survival benefits from immune checkpoint inhibitors. Thus, these findings may be helpful in the management of patients in clinical practice as well as develop novel treatment strategies in the future to improve the sensitivity of immunotherapy.


P. aeruginosa is a Gram-negative pathogen responsible for many serious infections. MDR, both intrinsic and acquired, presents major clinical challenges. Taniborbactam  is a β-lactamase inhibitor (BLI) characterized as a bicyclic boronate, uniquely possessing activity toward all four Ambler classes of β-lactamases, both serine and metallo, with the exception of class B IMP β-lactamases. The β-lactam-BLI (BL-BLI) combination cefepime-taniborbactam  is currently in phase 3 clinical trials.Structures of taniborbactam and cefepime. The β-lactamase inhibitor is in red and the β-lactam antibiotic is in black.P. aeruginosa isolates that were part of PRIMERS . Nearly 58% of these strains were reported as carbapenem-non-susceptible. Porin changes, efflux pumps, and/or the presence of acquired class A or class B carbapenemases were previously reported. Broth microdilution minimum inhibitory concentrations (MICs) were determined by CLSI M07 Ed. 11 methods with custom Sensititre frozen panels and interpreted using CLSI M100 Ed. 30 breakpoints. American Type Culture Collection strains were used for quality control. FEP breakpoints were provisionally used for FTB, where taniborbactam was fixed at 4 µg/mL.The activity of FTB was tested against 197 well-characterized clinical 50s were in the susceptible range for all drugs except IPM, which was intermediate, and all MIC90s were in the resistant range (Table 1). Taniborbactam reduced FEP MIC by 2-fold in 32% of isolates and ≥ 4-fold in 13% of isolates. Against carbapenem-non-susceptible strains, % susceptibilities were: FTB, 68.5%, CZA, 63.0%, C/T, 59.3%; and MVB, 21.3% (Table 2).Percent susceptibility to BL agents alone was 45.2% for imipenem (IPM), 55.8% for meropenem (MEM), 60.9% for ceftazidime (CAZ), and 67.0% for FEP. The addition of BLI to BL increased % susceptibility for MEM-vaborbactam (MVB), 56.9%; ceftolozane-tazobactam (C/T), 77.7%, CAZ-avibactam (CZA), 79.7%, and FTB, 82.7%. MICMIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for all P. aeruginosa strains (n=197). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021.MIC50 and MIC90 values (µg/mL) and percent susceptibility (%S) for the subset of carbapenem-non-susceptible P. aeruginosa strains (n=108). AMK, amikacin; ATM, aztreonam; C/T, ceftolozane-tazobactam; CAZ, ceftazidime; CZA, ceftazidime-avibactam; FEP, cefepime; FTB, cefepime-taniborbactam; IPM, imipenem; MEM, meropenem; MVB, meropenem-vaborbactam; TZP, piperacillin-tazobactam; TOB, tobramycin. *The breakpoints for FEP and MEM alone were provisionally applied to FTB and MVB, respectively. Tazobactam, avibactam, and taniborbactam were fixed at 4 µg/mL, while vaborbactam was fixed at 8 µg/mL. Breakpoints from CLSI M100, 31st ed, 2021.P. aeruginosa strains tested, including many carbapenem-non-susceptible strains. Pending completion of clinical development, FTB may be a promising therapeutic option for MDR P. aeruginosa infections.Compared to MVB, CZA, and C/T, FTB demonstrated the greatest activity against the 197 Robin Patel, MD, 1928 Diagnostics (Consultant)BioFire Diagnostics (Grant/Research Support)ContraFect Corporation (Grant/Research Support)Curetis (Consultant)Hylomorph AG (Grant/Research Support)IDSA Infectious Diseases Board Review Course Mammoth Biosciences (Consultant)NBME Netflix (Consultant)Next Gen Diagnostics (Consultant)PathoQuest (Consultant)PhAST (Consultant)Qvella (Consultant)Samsung Selux Diagnostics (Consultant)Shionogi & Co., Ltd. (Grant/Research Support)Specific Technologies (Consultant)TenNor Therapeutics Limited (Grant/Research Support)Torus Biosystems (Consultant)Up-to-Date  Robin Patel, MD, BioFire  Involved: Self): Grant/Research Support; Contrafect  Involved: Self): Grant/Research Support; IDSA  Involved: Self): Editor’s stipend; NBME, Up-to-Date and the Infectious Diseases Board Review Course  Involved: Self): Honoraria; Netflix  Involved: Self): Consultant; TenNor Therapeutics Limited  Involved: Self): Grant/Research Support; to Curetis, Specific Technologies, Next Gen Diagnostics, PathoQuest, Selux Diagnostics, 1928 Diagnostics, PhAST, Torus Biosystems, Mammoth Biosciences and Qvella  Involved: Self): Consultant David van Duin, MD, PhD, Entasis (Advisor or Review Panel member)genentech (Advisor or Review Panel member)Karius (Advisor or Review Panel member)Merck Pfizer Qpex (Advisor or Review Panel member)Shionogi Utility (Advisor or Review Panel member) Vance G. Fowler, Jr., MD, MHS, Achaogen (Consultant)Advanced Liquid Logics (Grant/Research Support)Affinergy Affinium (Consultant)Akagera (Consultant)Allergan (Grant/Research Support)Amphliphi Biosciences (Consultant)Aridis (Consultant)Armata (Consultant)Basilea Bayer (Consultant)C3J (Consultant)Cerexa Contrafect Debiopharm Destiny (Consultant)Durata Genentech Green Cross Integrated Biotherapeutics (Consultant)Janssen Karius (Grant/Research Support)Locus (Grant/Research Support)Medical Biosurfaces (Grant/Research Support)Medicines Co. (Consultant)MedImmune Merck (Grant/Research Support)NIH (Grant/Research Support)Novadigm (Consultant)Novartis Pfizer (Grant/Research Support)Regeneron sepsis diagnostics Tetraphase (Consultant)Theravance Trius (Consultant)UpToDate Valanbio xBiotech (Consultant) Daniel D. Rhoads, MD, Becton, Dickinson and Company (Grant/Research Support) Michael Jacobs, MBBS, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) Focco van den Akker, PhD, Venatorx Pharmaceuticals, Inc. (Grant/Research Support) David A. Six, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Greg Moeck, PhD, Venatorx Pharmaceuticals, Inc. (Employee) Krisztina M. Papp-Wallace, Ph.D., Merck & Co., Inc. (Grant/Research Support)Spero Therapeutics, Inc. (Grant/Research Support)Venatorx Pharmaceuticals, Inc. (Grant/Research Support)Wockhardt Ltd.  Robert A. Bonomo, MD, entasis (Research Grant or Support)Merck (Grant/Research Support)NIH (Grant/Research Support)VA Merit Award (Grant/Research Support)VenatoRx (Grant/Research Support)


Pancreatic cancer has a very low survival rate and improved treatments are required. In addition to tumour cells, the disease is characterized by a significant non-tumour cell stromal component including immune cells, blood vessels and, particularly, fibroblasts whose normal role is in connective tissue and healing wounds. This stromal environment can affect tumour progression and play a role in response to therapy. Whilst there is relatively good understanding of the deregulated signalling in the tumour cells, less attention has been paid to the stroma until recently. It is now apparent that there is significant variation within and between the stroma in different tumours, in particular, between fibroblast populations. TGFβ is a growth factor that can play a role in cancer cells, but also in shaping the tumour stroma. Here we review recent developments in our understanding of the fibroblast populations within PDAC with a focus on TGFβ signalling.Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few available therapies. It is notable for its high degree of tumour complexity, with the tumour microenvironment often accounting for the majority of the tumour volume. Until recently, the biology of the stroma was poorly understood, particularly in terms of heterogeneity. Recent research, however, has shed light on the intricacy of signalling within the stroma and particularly the molecular and functional heterogeneity of the cancer associated fibroblasts. In this review, we summarise the recent improvements in our understanding of the different fibroblast populations within PDAC, with a focus on the role TGFβ plays to dictate their formation and function. These studies have highlighted some of the reasons for the failure of trials targeting the tumour stroma, however, there are still considerable gaps in our knowledge, and more work is needed to make effective fibroblast targeting a reality in the clinic. Over the last 50 years there has been very little improvement in survival of patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) with only 8% of patients in the UK surviving 5 years post diagnosis . AlthougTP53, SMAD4 and CDKN2A found in ~50% of cases. However, the publication of multiple human PDAC sequencing experiments has highlighted the abundance of low penetrance gene mutations. These studies also allow for broad clustering of patients into specific cancer subtypes while highlighting commonly dysregulated signalling pathways [With the failure of non-specific chemotherapy, patient stratification remains an attractive option to identify subsets of patients that would respond well to targeted therapies. Constitutively active KRAS is found in 95% of PDAC cases, with mutations in pathways ,7,8. PatEvolving alongside the cancer cells, there is a significant stromal component in pancreatic cancer, consisting of fibroblasts and immune cells and an abundance of extracellular matrix (ECM), together constituting up to 80% of the total PDAC. Although our understanding of the genetics of disease progression has improved, little attention has been paid to this stromal infiltrate until more recently. A large proportion of the stroma is made of cancer-associated fibroblasts (CAFs) which have been proposed to have both a tumour restraining and promoting function . RecentlTGFBR2), TGFBR1 and SMAD4 in human PDAC [One of the major dysregulated pathways within PDAC is transforming growth factor beta (TGFβ) signalling. The TGFβ signalling family is composed of 33 ligands and in its simplest form involves ligation of a type II receptor which recruits and phosphorylates a type I receptor at the cell surface to propagate intracellular signalling via SMAD molecules. Complexity is imbued by the range of ligands and varied receptor combinations, as well as cell and context specific functions. For instance, TGFβ has been shown to be potently tumour suppressive in disease initiation as illustrated by the frequent mutations to signalling components, TGFβ-receptor-2  [Tgfbr2 also accelerated KRAS-driven carcinogenesis with a median survival of less than 2 months [TGFβ signalling has been shown to be a potent tumour suppressor in pancreatic cancer. Disruption of signalling, primarily through a (IPMN) ,17,18. F2 months , highlig2 months . In cont2 months ,21,22, t2 months . Interes2 months .Tgfbr1 deletion. Epithelial depletion of the type 1 receptor promoted pancreatic tumourigenesis, in line with findings in Smad4 and Tgfbr2 deficient models, however, systemic depletion revealed important TGFβ-mediated control of the tumour microenvironment (TME). Tumourigenesis was delayed, production of TGFβ ligand by the stroma was diminished as a result of the disruption of positive feedback caused by receptor depletion, and tumour-associated fibrosis was decreased. In addition, the TME was converted to a less immunosuppressive state, with a decrease in Treg infiltration and significant CD8+ T cell infiltration observed [G12D; Cdkn2alox/loxp48-Cre; LSL-Kras autochthonous model of PDAC and in orthotopic models, resulted in a reduction in αSMA fibroblasts with a subsequent reduction in collagen deposition, tumour cell differentiation and reduced metastases [TGFβ signalling has been shown to have an important role in the stromal reaction in cancer , and speobserved . Furthertastases . TogetheIn terms of the downstream effects of TGFβ signalling in the stroma, TGFβ treatment of both fibroblasts and CAFs has been shown to lead to increased cell stiffness, and specifically in CAFs, to enhanced cell elongation and spreading, formation of lamellipodia and invasion. Mechanistically, these changes are accompanied by increased Rac, RhoA and ROCK . Biffi eKras model demonstrating resolution of neoplastic regions, but also of the associated infiltrated stroma, upon ‘switching off’ of oncogenic Kras [In PDAC, a large proportion of the TME is composed of CAFs, which develop alongside the growing tumour and contribute significantly to fibrosis. The ECM of both primary and metastatic sites of PDAC is composed of significant levels of collagens I, III and IV, as well as hyaluronan, with high levels denoting worse prognosis . Stromalnic Kras . HoweverPSCs were initially isolated from the rat pancreas  and wereIt has also been demonstrated, however, that CAFs isolated from human PDAC can arise from mesenchymal stem cells (MSCs). Waghray and colleagues found that a population of these CAFs expressed multiple MSC markers in addition to bona fide CAF markers vimentin, fibroblast activation protein (FAP) and αSMA. These MSC-derived CAFs secreted various cytokines such as IL-6 and IL-8 but exclusively expressed granulocyte macrophage-colony stimulating factor (GM-CSF) differentiating them from other CAFs. The production of GM-CSF from these cells was able to enhance invasion of cultured cancer cells .Further, it has recently been shown that CAF-like cells may be derived from bone marrow (BM)-derived monocytes that infiltrate the tumour. Transplantation of GFP-positive BM into spontaneous mouse models of PDAC highlighted a population of GFP, F4/80 and podoplanin (PDPN) positive cells, a macrophage and pan fibroblast marker, respectively, found even in MSC depleted samples. These cells were shown to be either αSMA positive or negative and able to produce an array of cytokines in culture, including IL-10 and IL-6 .+ and Hoxb6+ fibroblast within the pancreas highlighted divergent expansion upon oncogenic transformation. Intriguingly, the authors show the existence of both PSCs and fibroblasts (lacking lipid droplets) within the healthy pancreas, with Gli1+ fibroblasts found in perivascular regions and Hoxb6+ fibroblasts scattered throughout the pancreatic parenchyma [+ fibroblasts failed to expand upon development of neoplasia, the Gli1+ fibroblast population was shown to expand and contribute to the αSMA+ fibroblast population during tumourigenesis. However, in terms of αSMA expression, heterogeneity existed across Gli1+ lineage cells [Recently, lineage tracing of Gli1renchyma . Whereasge cells . Interesge cells . Conversge cells . Crosstage cells . The impTogether these studies suggest that fibroblast heterogeneity is present in the normal pancreas but is also derived from the infiltration or expansion of cells in pancreatic tumours that can develop CAF-like features and functions. More recently, the field has begun to appreciate that CAFs in PDAC may differ not only in their cell of origin but also in function . These fG12D-transformed cancer cells were shown to regulate the secretome of PSCs [G12D was sufficient to drive MEK-ERK signalling but not AKT activation, which required secretion of IGF1 and GAS6 by the PSCs [It is important to understand how these heterogeneous populations of CAFs can influence tumour cells and other cells in the TME and to characterize the crosstalk between different cell populations. Indeed, communication between CAFs and tumour cells is highly complex, and not limited simply to one directional paracrine signalling. For example, CAFs and tumour cells can form a reciprocal signalling loop, whereby CAFs educated by the tumour cells can in turn impact oncogenic signalling in the cancer cells. In one study, KRAS of PSCs . Intriguthe PSCs . Furtherthe PSCs . Transcrthe PSCs . TogetheAs well as stimulating EMT, the fibrotic stroma driven by CAFs has been proposed to impair drug delivery into tumours resulting in highly chemoresistant tumours . TargetiMultiple studies have sequenced human PDAC and have exposed a range of cancer specific subtypes, highlighting multiple high and low penetrance mutations across the disease . Until rThese findings highlighted the inter-tumoural heterogeneity of the PDAC stroma and suggested that a specific stromal signature could influence patient prognosis. They convincingly show that patients can present with different stromal composition within PDAC, with cancer cell subtype not necessarily defining a specific stromal type, although combinations of each may predict worse outcomes. However, there are limitations in analysing CAF-specific functions when analysing bulk stroma, which incorporates CAFs, immune cells and endothelial cells. Therefore, subsequent studies have applied CAF culturing, single cell sequencing (scRNA-seq) and cytometry by time of flight (CyTOF) to investigate, at single cell or population resolution, the fibroblast heterogeneity within PDAC.RNA sequencing of low passage CAFs derived from human PDAC samples highlighted both inter- and intra-tumoural CAF heterogeneity, with four subtypes defined. From the transcriptional signatures, the authors of this study were able to define specific markers for subtypes A, B and C, , respectively), which stained in distinct spatial regions of PDAC . InteresExtensive work from the Tuveson lab has uncovered three distinct fibroblast subpopulations within PDAC, termed ‘myCAFs’, ‘iCAFs’ and ‘apCAFs’. Initial work, both in organoid co-cultures and in vivo, documented the existence of myofibroblast-type (myCAF) and inflammatory (iCAF) CAFs. The myCAF population was shown to exist in close proximity to neoplastic cells, expressed high levels of αSMA and TGFβ response genes, and was largely responsible for ECM deposition. In contrast, the inflammatory CAFs (iCAFs), named for their chemokine secreting capability, were found distant from cancer cells, expressed significantly lower levels of αSMA, and instead were characterized by secretion of factors such as Il-6, Il-11, LIF, CXCL1 and CXCL2 . Both suCre/+; KrasLSL-G12D/+; Ink4afl/flPtf1a (KIC) mouse model of PDAC, before validation in a p53-deficient model. They demonstrated that three populations of fibroblasts were present in normal pancreas and in expanded numbers in early lesions, however, in PDAC this converged to just two fibroblast populations [Distinct fibroblast populations were also identified in a study in which the authors performed scRNA-seq on normal pancreas, PanIN-bearing pancreas and PDAC from the ulations . In the ulations ,12. CD74Further confirmation of these CAF subtypes was provided by Steele et al., when they analysed a single cell sequencing data set of PDAC ,60. HoweYet another marker that could distinguish CAF populations was identified by the Turley lab. They conducted single cell sequencing of PDPN+ fibroblasts from murine PDAC and observed several transcriptionally distinct CAF populations which converged into two populations driven by IL-1 or TGFβ, reminiscent of iCAFs and myCAFs. The TGFβ-driven population represented ~60% of all CAFs in late-stage tumours, despite being absent in normal pancreas, and was defined by expression of the leucine-rich repeat containing 15 (LRRC15) protein. This population was also observed in human tumours, with clinical trial data showing that the LRRC15+ CAF signature was associated with poor response to immunotherapy, suggesting an immunosuppressive role for these cells .Other CAF markers which imply CAF plasticity have been identified. For example, Fujiwara et al. found that the putative mesenchymal stem cell marker, CD271, was elevated in the stroma of PDAC compared to normal pancreas, predominantly at the tumour periphery. However, high stromal CD271 expression was associated with improved prognosis in pancreatic cancer patients. In PSC-tumour cell co-culture experiments, CD271 expression in PSCs was increased initially, but decreased upon prolonged co-culture, suggesting that expression decreases after prolonged exposure to tumour cells . A more Prrx1 deletion led to more differentiated, less metastatic tumours, alongside changes to the tumour ECM, and this phenotype was attributed to release of hepatocyte growth factor (HGF) driving EMT in tumour cells [Prrx1-deficient CAFs recapitulated many of the features of myCAFs, but unlike myCAFs, were fixed in their activated state when cultured in Matrigel, suggesting that PRRX1 may be key for mediating CAF plasticity.Recently, the transcription factor, paired-related homeobox 1 (PRRX1), has also been suggested to play a role in CAF plasticity. It was reported to be highly expressed in CAFs in both mouse and human PDAC, with stromal PRRX1 expression correlating with the basal/squamous PDAC subtype. In mouse models, fibroblast-specific ur cells . This waur cells . One opeRecently, the Jørgensen lab described an alternative CAF classification based on expression of CD105, a co-receptor for TGFβ. Using mass cytometry to analyse the stroma in pancreatic tumours arising in autochthonous mouse models they identified two functionally distinct pancreatic fibroblast lineages which were also present in normal pancreas as well as in human PDAC and normal healthy pancreas. The CD105+ fibroblasts were more abundant in tumours, however, CD105- CAFs were more proliferative within tumours, and a minority of tumours showed an abundance of CD105- CAFs . Of the Eng, the gene encoding CD105, from CD105+ CAFs did reduce transcriptional responses to TGFβ1 treatment. Interestingly, however, any function attributable to CD105 did not play a role in tumour suppression, since Eng deletion from CD105+ cells was not sufficient to affect tumour growth [In co-transplant experiments in mice, CD105+ PaFs were permissive for tumour growth in that they did not significantly influence tumour volume. However, CD105- PaFs were revealed to be highly tumour-suppressive—co-injection of this population markedly constrained tumour growth and led to improved survival, an effect recapitulated even when a 1:1 mixed population of fibroblasts were co-injected. CD105- co-injected tumours showed increased infiltration of dendritic cells (DCs) and CD8 T cells, and pathway analysis revealed an enrichment for pathways involved in tumour-suppressive immune responses including DC maturation and T cell activation, suggesting this tumour-restrictive effect is dependent on adaptive immunity. Indeed, the tumour suppressive effect was lost in immunodeficient mice and in mice lacking conventional type 1 dendritic cells (cDC1s). Although no signalling capacity has been reported downstream of CD105, it has been shown to alter the affinity of ligands for the TGFβ receptor complex and deletion of r growth .Collectively, these papers highlight inter- and intra-tumoural heterogeneity through multiple techniques .It is worth noting the caveats of these single cell systems, which involve the dissociation of the tumour with the potential of altering the cell transcriptome. However, combining these data with functional data and in situ validation in tumour tissue has allowed verification of the findings of the single cell experiments. Although our understanding continues to improve, a consensus is still to be met upon fibroblast subpopulations definitions. Across studies, subtypes have varied in definition, with different IHC markers defining different subpopulations. It is key, not only to pinpoint bona fide markers for these subsets, but also to better understand the function of these sub-populations and the effects of their manipulation in complex tumours in order to enable the stratification of patients and understand how variations in CAF composition of patient tumours might represent therapeutic vulnerabilities.SMAD4 resulting in a stiffer fibrosis which correlates with a poorer survival [Tgfbr2 deficient mice highlighted a similar phenotype with a stiffer ECM in comparison to the gold standard KPC  model [Tgfbr2 deficient mice to show that myofibroblast depletion led to more aggressive tumours and reduced survival, although they obtained similar results in the KPC model [Adding a further layer of complexity, the genetics of PDAC may directly impact the TME with, for instance, the loss of survival . Work in+) model , and thi+) model . InteresPC model .Robo2 deletion, expansion of ROBO1+ activated myofibroblasts was observed along with induction of TGFβ signalling. In vivo, the Robo2-deficient mice exhibited TGFβ-dependent increased fibroblast activation, fibrosis and immune signalling markers in response to experimental pancreatitis, while in PDAC patients, low ROBO2 expression high ROBO1 expression were associated with poorer survival. Thus, perturbations in ROBO1/2 signalling could indicate a patient subgroup who could respond to TGFβ or stromal targeting agents [Recurrent mutations in the SLIT/ROBO pathway have been described in human PDAC  and may g agents .R172H mutant KPC tumours were shown to create a more collagen dense environment in comparison to those isolated from p53-deficient KPflC  tumours [R172H tumour cell-educated CAFs created a stiffer matrix that could enhance the invasion of the less metastatic p53-deficient cancer cells, potentially via secretion of perlecan, which was elevated in mutant p53-educated CAFs, as well as in the stroma of KPC vs. KPflC PDACs. Interestingly, given its role in driving the iCAF phenotype, TNFα was able to enhance perlecan expression by the KPflC educated CAFs [+ T cells in mouse and human PDAC [Even different mutations within the same gene may affect CAF biology. CAFs from p53 tumours . The gaited CAFs ,72. Gainman PDAC .Epigenetic changes may also influence CAF plasticity. For example, matrisomal gene expression was shown to be dependent on BET family proteins mediating crosstalk between tumour cells and CAFs, with a small molecule inhibitor able to alter matrisome gene expression and inhibit tumour growth in mouse models . Xiao etCre; KrasLSL-G12D/+; Trp53fl/flPdx1 mouse models of PDAC has highlighted a similar clustering of CAFs [It is not surprising to note that the genetic aberrations within PDAC, which have the capacity of altering the wider TME through direct and long-range signalling, can influence the CAFs. It does, however, add complexity to our understanding of CAF subtyping with the predominance of work focussing on the KPC mouse model, reflecting the frequent gain of function p53 subtype of human patients. It will be interesting to discover whether the current CAF subtyping definitions are similar in other genetic models of PDAC, and whether the subtype proportions change with differing genetic education. Examination of late-stage tumours in the KIC, KPC and  of CAFs , suggest of CAFs ,78. Conv of CAFs . HoweverWith the general failure of frontline therapies in the treatment of PDAC, extensive research has been conducted to identify new therapeutic avenues. Stratified therapy appears an exciting option due to the ability to cluster patient subsets based on genetic permutations, which may expose new vulnerabilities. However, as our understanding of fibroblasts heterogeneity increases, this field may provide new targets to influence ‘good’ or ‘bad’ fibroblasts or to reprogram the TME.Early studies in PDAC suggested that the fibrotic stroma could restrict chemotherapeutic penetrance, and therefore proposed therapeutic targeting of stromal elements in combination with chemotherapy. In 2009, work by Olive and colleagues in PDAC mouse models found that targeting SHH signalling, a known driver of desmoplasia in pancreatic cancer , could dShh deletion, chronic pathway inhibition or depletion of αSMA fibroblasts resulted in more aggressive, poorly differentiated tumours and reduced survival in KPC mice [Tgfbr2, and although canonical TGFβ signalling is thought to antagonize iCAFs, TGFβ stimulation of CAFs led to upregulation of IL-6 and LIF via non-canonical signalling through JunD [Subsequent preclinical studies attempted to understand the reasons for these failures. Genetic models assessing the effects of pancreatic epithelial KPC mice ,85,86. IKPC mice . Work byKPC mice , suggestKPC mice . The iCAKPC mice , which iKPC mice , and thiugh JunD . + fibroblasts, accelerated pancreatic tumourigenesis in a dual recombinase mouse model of PDAC. Interestingly the lack of collagen I in this situation did not affect the proportions of fibroblast subpopulations, as determined by single cell RNA sequencing, but did result in poorly differentiated, immunosuppressed tumours. Although αSMA is expressed across most CAF subtypes, the myCAFs exhibit the highest expression and are also the major producers of ECM. Interestingly, collagen I deletion from fibroblast specific protein 1 positive fibroblasts had no effect on survival [Recent studies have sought to target CAF function, rather than ablating whole populations. For example, perlecan deletion from KPC tumour-educated CAFs promoted sensitivity to gemcitabine–abraxane combination therapy in a co-transplant orthotopic model . In contsurvival . This stsurvival  was ablesurvival . Indeed,survival . TherefoEnhanced drug efficacy in tumour cells has been a goal of many studies investigating stromal manipulation in PDAC. However, conversely, tumour cell-targeted therapies may also have consequences in the TME and on the CAFs. In general, CAFs appear to be resistant to gemcitabine in terms of survival, indeed, they have been reported to sequester active gemcitabine metabolites, thus protecting tumour cells . Their r+ CAFs vs. CD105- CAFs [Chemotherapy can also indirectly affect the output of CAFs as a consequence of deregulated stromal-tumour crosstalk. For example, Abraxane treatment can drive CXCL10 expression by PDAC cells, resulting in diminished CAF secretion of IL-6 and reduced cancer cell migration and invasion . Long-te05- CAFs .Tgfbr2 mutations showed an increased immune infiltration when treated with a TGFβ-R2 inhibitor, thereby depleting TGFβ signalling in stromal cells only [Of course, care needs to be taken when employing TGFβ-targeting strategies. In the tumour cells, TGFβ signalling has clear tumour-suppressive effects, and TGFβ inhibition alone had been shown to exacerbate disease in mice in both early and late intervention studies . Neverthlls only . In contlls only .Cytokine education of CAFs has also been shown to impact on their function and may yet provide a therapeutic opportunity. For instance, IL-17 deletion in the KPC mouse altered the TME compared to controls, with increased IL-17F in the serum and higher expression of its receptor specifically in the CAFs in IL-17 deficient tumours. The CAFs from IL-17 deficient tumours exhibited significant gene expression changes including elevated TGFβ signalling components. Fibrosis was enhanced but crucially, the stroma was of a less compact and more immune-permissive nature resulting in increased T cell infiltration and suggesting the use of IL-17 inhibitors as part of combinatorial strategies .These studies all point to an important role for TGFβ signalling in the wider PDAC TME, but further work is needed to understand how this can be translated safely for therapeutic benefit. The pancreatic cancer stroma is generally believed to be an immunosuppressive environment, and this is likely mediated in part by the secretion of immunosuppressive factors such as TGFβ since TGFβ can regulate the function of many different immune cell types . TGFβ siTGFβ targeting may also have consequences in other immune cells that could be harnessed as part of combinatorial approaches. For example, TGFβ can negatively influence the tumour immune response via its capacity to inhibit the maturation and antigen-presenting ability of dendritic cells, as well as to dampen the activity of effector T cells and promote Tregs . AdoptivIn conducting pre-clinical and clinical trials there is now a clear need to measure the impact treatment has upon the wider TME, especially the CAFs, not only to better understand the biology, but also to reveal vulnerabilities that may suggest combinatorial or second-line strategies. For instance, the TGFβ inhibitor combinatorial trials described above have demonstrated moderate efficacy in patients, but it would of course be useful to know how therapy affected CAF subpopulations. Further study should dissect where inhibition of TGFβ signalling is having the biggest effect in these tumours, whether through disrupting CAF pro-tumorigenic function or via relieving immune suppression, or more likely, both (as illustrated in Over the past few years, advances in our understanding of the heterogeneity of CAFs in the pancreatic cancer microenvironment have offered renewed hope that stromal-targeted therapies could still hold promise in this disease. It is clear from functional studies, however, that CAF heterogeneity is not restricted simply to expression of specific markers, and that populations exist that exhibit both tumour-promoting and tumour-restrictive behaviours. Therefore, rational approaches to target tumour-promoting CAF behaviour, rather than targeting all CAFs, will be required. This could be achieved by converting tumour-promoting CAFs into a more tumour-suppressive phenotype, ablation of a tumour-promoting population, targeting of specific tumour-promoting secreted chemokines or cytokines, such as TGFβ, or by a combination of these approaches. It is likely that any effective regimen will also include chemotherapy and potentially immune-targeting therapy, and that patient stratification will be important. It is clear, however, that in order to elucidate how different populations can be targeted but also to understand the effects of subtype targeting in complex systems, a great deal more work is required.


In univariate analysis, NLR (>0.745)) in malignant pleural fluid was predictive of poorer survival , and remained significant after adjustment for age, sex, presence of a chest drain, cancer type, concurrent infection and subsequent treatment with chemotherapy . Patients with pleural fluid NLR > 0.745 had a significantly shorter median survival of 130 (95% CI 0–282) days compared to 312 (95% CI 195–428) days for pleural NLR < 0.745, p = 0.026. The NLR in blood was also predictive of poorer survival in MPE patients . The proportion of neutrophils in pleural fluid was predictive of prognosis more strongly than lymphocytes. This study provides evidence that NLR in malignant effusions can predict survival, and therefore may provide prognostic information for this cohort. This prognostic association in the fluid is driven by the presence of neutrophils.Predicting survival of patients with malignant pleural effusions (MPEs) is notoriously difficult. A robust prognostic marker can guide clinical decision making. The neutrophil-to-lymphocyte ratio (NLR) in blood has been shown to predict survival in many cancers. Pleural fluid bathes the malignant pleural tissues, thus the NLR of the pleural fluid may reflect more closely the local tumour environment. The objective of this study was to explore the prognostic significance of pleural effusion NLR for MPE. We analysed matched effusion and blood from 117 patients with malignant and 24 with benign pleural effusions. Those who had received recent chemotherapy or had a pleurodesis were excluded. Neutrophil and lymphocyte counts in effusions were performed by manual review of cytospin cell preparations by trained observers. Clinical data were extracted from a state-wide hospital database. We found significantly fewer neutrophils  in pleural fluid than in corresponding blood . The NLR was an order of magnitude lower in pleural fluid than in corresponding blood: median [IQR] = 0.20 [0.04–1.18] vs 4.9 [3.0–8.3], p<0.001. Correlation between blood and pleural fluid NLR in MPE patients was moderate (r Malignant pleural effusion (MPE) often indicates advanced, disseminated malignancy. MPE most commonly develops due to lung, breast, gastrointestinal and gynaecological cancers as well as malignant mesothelioma (MM). Shortness of breath from the underlying pleural effusion is the most common presenting symptom and is often relieved by pleural fluid drainage. Prognosis of patients with MPE can range from 1 to 18 months and can be dependent on the underlying aetiology and cancer staging . PredictSymptom control is the primary goal of MPE management and can be achieved through a number of invasive procedures. Treatment choices including chemotherapy or effusion control strategy, may be guided by prognosis. These procedures may not be appropriate for patients with a poor prognosis where palliative approaches and thoracentesis can provide transient relief of symptoms in the short-term whilst minimising discomfort. Stratifying patients with MPE based on survival is therefore essential to facilitate appropriate treatment choices.Most of the research efforts to date on prognostication of MPE patients have focussed on clinical  in blood is a recognized surrogate marker of inflammation and immune response. An elevated blood NLR is associated with poor survival in MPE , 5 and iAll patients with MPE have pleural fluid sampled for cytological analysis and therefore the NLR is easily available. Examining pleural fluid NLR may provide insight into whether the prognostic power of blood NLR is a reflection of the tumour immune milieu or systemic events. The objective of this study was to explore the prognostic significance of pleural effusion NLR for MPE. A recent study in patients with non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) wild-type patients found that pleural NLR was predictive of survival , althoug6 total cells that were processed immediately were included. Samples were centrifuged at 1000 g for 10 minutes and re-suspended as a single cell suspension in RPMI-1640 media (Invitrogen) and 10% foetal calf serum (Invitrogen) and centrifuged onto a microscope slide using a StatSpin Cytofuge 2 (Beckman Coulter) following the manufacturer’s instructions. Cytospins were stained using Rapid Stain (Amber Scientific) and 400 cells per slide were manually reviewed and classified as tumour, mesothelial, macrophage, lymphocyte, neutrophil, eosinophil or other by a cytopathology technician (AM) and an experienced trained researcher (CG). Cronbach’s alpha test of internal consistency confirmed excellent inter-observer variability with above 0.900 scored for 4 of 5 categories and 0.844 for the remaining one.Pleural fluid samples of patients attending Sir Charles Gairdner Hospital in Perth, Western Australia were prospectively collected between January 2010 and December 2015 from patients who provided informed written consent. Inclusion criteria included the presence of a pleural effusion requiring drainage; exclusion criteria included concomitant immunosuppressive medication usage, age less than 18 years, pregnancy and inability to provide informed consent. This study was approved by the Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics committee. Samples were collected in sterile containers following pleural drainage and immediately transferred at ambient temperature to the laboratory. Samples with >100mL and with > 5 x 10The hospital databases were interrogated for clinical  and laboratory data of individual patients. In particular, blood total  leucocyte counts performed within 24 hours of the collected pleural sample were also identified. Chemotherapy treatment data were confirmed through pharmacy dispensing and medical records. Survival data were censored on 16 August 2016.Samples were classified based on pathological, biochemical and clinical review as malignant or benign pleural effusions. Malignant effusions all had histo-/cyto-logical and ancillary immunostaining confirming cancer cells were present in the pleural fluid or tissue biopsy, and/or were an effusion in a patient with known metastatic cancer where there were no alternative fluid aetiologies. MPE were further classified as being related to MM or other cancers. Benign effusions were classed as exudates or transudates by Light’s criteria  and confWhere multiple pleural samples were available from an individual patient, the first available sample according to collection date with a matching blood leukocyte count that met inclusion and exclusion criteria was included. Samples were excluded if the patient received recent chemotherapy as this may affect leukocyte counts. Exclusion times from chemotherapy were based on standard nadir recovery ranges for each specific chemotherapy agent , 17. SamNLR was calculated by dividing the absolute neutrophil and lymphocyte counts obtained in blood or pleural fluid. The percentage of neutrophils and lymphocytes in blood and pleural fluid was calculated from the total leukocyte count.http://molpath.charite.de/cutoff/) was used, to determine the value that optimized the log-rank test significance between the two groups. Significance was defined as p<0.05.Data were analysed using SigmaPlot 12.5 , and presented as mean (±SD) or median [IQR] based on normality of data. The Wilcoxon Signed-Rank test and paired t-test were used for analyses of non-parametric and parametric data respectively. The Pearson and Spearman Rank Correlations (for parametric and non-parametric data respectively) were used to determine any relationship between serum and pleural fluid NLR. Survival analysis was performed using Cox proportional hazards regression and data reported with 95% confidence intervals. Median survival times between groups was calculated from the Kaplan Meier survival estimates, using SPSS . For the purpose of dichotomizing NLR and cell percentage variables into groups, Cutoff Finder  of cases, with 213 MPE and 29 benign effusions identified. Multiple samples available from the same individual (n = 43) resulted in 89 samples being excluded with a further 12 samples excluded due to recent chemotherapy and 1 sample excluded as it was identified as a peritoneal  effusion . No sampeffusion .In total 141 paired blood and pleural fluid samples (117 MPE and 24 benign effusions) formed the analysis set. Most patients (84%) were male and 68 (±13) years of age. MM was the cause of MPE in over half  of cases. Samples were collected at a median of 161 (22–459) days following diagnosis of malignancy in the MPE cohort .At census, 77% (n = 90) of patients with MPE (79% of the non-MM and 75% of the MM cohort) were deceased. The median survival time for patients with MPE from sample collection was 285 (IQR 216–814) days. Survival of MM and other cancer cohorts are presented in s = 0.232, p = 0.006) and lymphocytes  in blood and pleural fluid was observed.Neutrophils, presented as a percentage of total leucocytes, were significantly lower in the pleural fluid  than in blood , p<0.001 . ConversBenign pleural effusions (33% [3–61]) had a significantly higher proportion of neutrophils than MPE  and without (n = 101) concurrent infection  although there was a significant difference in pleural fluid neutrophil percentages  . Pleural NLR was lower in malignant effusions than in benign ones . MPE patients with a chest tube or IPC had comparable NLR levels to those without . Correlation between blood and pleural fluid NLR in MPE patients was moderate (r <0.001) .The NLR within pleural fluid of patients with MPE was identified as an individual predictor of overall survival in a univariate analysis , For patients with MPE, the NLR in the blood as a continuous variable, was predictive of survival . Patients with blood NLR ≥ 5 had a median survival of 130 (95% CI 64–195) days from sample collection compared to 479 (95% CI 289–669) days for NLR < 5, p<0.001 . MultivaSurvival analysis revealed that per unit increase, neutrophil percentages within the blood and fluid were significant prognostic factors . The proThe proportion of lymphocytes in MPE was evenly distributed . No assoThis study of pleural fluid NLR finds that the proportion and distribution of neutrophils and lymphocytes differed considerably between the blood and pleural fluid suggesting that the pleural immune/inflammatory responses are, in part, compartmentalized. In this hypothesis generating study, the pleural fluid NLR predicted prognosis. The percentage of neutrophils within the pleural fluid, but not the lymphocytes, was associated with poor survival, suggesting that in the effusion NLR is driven by neutrophils.Systemic NLR has been validated as a prognostic biomarker in many cancers , 18. OurMPEs develop at the site of the pleural tumour therefore the NLR within the effusion itself allows assessment of the immunological cellular milieu in the malignant environment. There was a weak, but significant, monotonic relationship between blood and effusion NLR, as well as distinctly different levels in the two compartments, and our study supports that NLR in effusions may have prognostic value. There was an inverse linear relationship between effusion NLR and survival which suggests a dose-related effect. However, the dichotomised threshold value for the NLR used in this study will need to be validated and optimized in larger future studies.NLR as a biomarker, reflects overall immunological status. In blood we noted that as independent variables both the higher percentage of neutrophils and the lower the percentage of lymphocytes were predictive of poor survival confirming findings from previous studies in multiple tumour types including prostate, nasopharyngeal, gastric, renal, lung and NSCLC –26. In eThe limitation of this study is the lack of validation in an independent cohort. Furthermore, our cohort had a high proportion of patients with MM due to local prevalence. However systemic NLR has been shown to reflect prognosis of MM as it does for common metastatic pleural cancers that cause MPE. Also, patients on recent chemotherapy were excluded, as this can induce acute neutropenia and may not be reflective of the ongoing tumour-immune interaction; however, excluding these patients may not reflect real life situations of sampling. Despite the heterogeneity of the cohort we confirmed previous findings that blood NLR was an independent predictor of prognosis, which supports the validity of the cohort. A strength of our study was that samples were included from any time point following diagnosis (median 182 days) and therefore may have greater clinical relevance as prognostic markers.This study describes the neutrophil and lymphocyte distributions in MPEs from various aetiologies and found a prognostic value of pleural fluid NLR and of pleural fluid neutrophils . Further studies are needed to determine whether pleural fluid NLR may be a simple and useful biomarker for predicting prognosis in patients with malignant effusions.S1 Table(XLSX)Click here for additional data file.


Glioblastomas (GBMs) are the most aggressive primary brain tumours and have no known cure. Each individual tumour comprises multiple sub-populations of genetically-distinct cells that may respond differently to targeted therapies and may contribute to disappointing clinical trial results. Image-localized biopsy techniques allow multiple biopsies to be taken during surgery and provide information that identifies regions where particular sub-populations occur within an individual GBM, thus providing insight into their regional genetic variability. These sub-populations may also interact with one another in a competitive or cooperative manner; it is important to ascertain the nature of these interactions, as they may have implications for responses to targeted therapies.We combine genetic information from biopsies with a mechanistic model of interacting GBM sub-populations to characterise the nature of interactions between two commonly occurring GBM sub-populations, those with EGFR and PDGFRA genes amplified. We study population levels found across image-localized biopsy data from a cohort of 25 patients and compare this to model outputs under competitive, cooperative and neutral interaction assumptions. We explore other factors affecting the observed simulated sub-populations, such as selection advantages and phylogenetic ordering of mutations, which may also contribute to the levels of EGFR and PDGFRA amplified populations observed in biopsy data. Standard treatment consists of surgically removing as much of the tumour as thought safe, followed by radiation and the chemotherapy temozolomide . In spitA major factor that is thought to contribute to treatment failure is the heterogeneous nature of GBMs. These tumours are known to be comprised of multiple sub-populations of cancerous cells, each with different genetic and phenotypic features . FurtherOver recent years, advances in biopsy sampling techniques have been helping to characterize this inter- and intra-tumoural genetic heterogeneity exhibited by GBMs. Treatment decisions are based on the biomarkers present within a single biopsy specimen, which may only be representative of a small part of the tumour. This means that clinical decisions made based on this knowledge may not be the optimal therapeutic strategy to target the majority of cancerous cells composing the rest of the tumour, which may have different genetic features and respond better to another treatment option. Therefore, in order to gain more understanding of the genetic heterogeneity across the tumour region, image-localized multiple biopsy sampling techniques have been developed, allowing surgeons to collect multiple tissue samples from an individual during surgery and record information about the location in the tumour from where the sample was taken. Subsequent tissue analysis then identifies how the genetic profile of these samples differs from one region of the tumour to another, providing spatial and genetic information that gives insight into the inter- and intra-tumoural heterogeneity present in these complex tumours; examples of such techniques being employed can be found in –9.While the exact mechanism by which such genetic heterogeneity arises in GBMs is currently unknown, several possible theories have been proposed to explain this. These include the theory of clonal evolution, where tumours are thought to evolve through a process of acquiring mutations and natural selection; the cancer stem cell (CSC) model, in which a small population of CSCs give rise to and maintain the tumour through self-renewal and producing phenotypically diverse daughter cells; or possibly some complementary combination of these two theories . In addicopy number aberration, it also induces overexpression of these genes in tumour cells , with zero flux boundary conditions at x = 0, L, and the initial conditions given by,E, P and N are the concentrations of each of the tumour cell sub-populations (cells/mm3) and N tumour cells. Thus we initiate our simulations with no E or P cells present and a small population of type N cells.Our model, therefore, takes the form of an extended PI model to account for the evolution of three genetically-distinct sub-populations defined as tumour cells with the genes encoding for EGFR . We choose to incorporate this non-linear form of diffusion in our model, since we expect the migration of tumour cell sub-populations to be affected by the presence of other tumour cells and derive these terms following the volume-filling approach of Painter and Hillen [maximum carrying capacity (K), can fill a given volume, which we assume to be the same for each of the cell populations E, P and N; other approaches to modelling the migration of multiple GBM tumour cell sub-populations can be found in [K . The parameters αEP and αPE measure the effect of sub-population E on sub-population P and vice versa. For example, if αEP > 0 in E, promotes proliferation of the PDGFRA amplified (PDGFRAamp) population, P; this could be due to secretion of a growth factor that PDGFRAamp cells are sensitive to, for example. Alternatively, if αEP < 0, then the net proliferation of PDGFRAamp cells reduces as the density of the EGFRamp population increases and the PDGFRAamp cells are negatively affected. Furthermore, if αEP = 0, then sub-population E has no effect on the net proliferation of P. The parameter αPE is defined analogously and we note that if both αEP and αPE are zero, then there are no additional interactions between the two populations, only competition for space. We define the types of interactions that can occur between EGFR and PDGFRA amplified sub-populations in our model and summarise them in The other factors in the above proliferation terms can be thought of as modified net proliferation rates, where the parameters E or P is present initially in our model with the initial conditions defined by N) and amplification of the EGFR and PDGFRA genes arises via mutations at later times [E and P, arise in the model through the terms mE and mP in mE = mE and mP = mP to be of the following form,δ(·) is the Dirac delta function, E and P, are introduced as Gaussian distributions centred at N) has grown to a chosen total size, NE or NP (measured in cells/mm2). Our choices for NE or NP are discussed further in Neither sub-population er times , consister times . Thus, tαEP = αPE = 0, and all three sub-populations diffuse and proliferate at the same rates, i.e., DE = DP = DN and ρE = ρP = ρN, then the system can be reduced to a single equation governing the total population of tumour cells, T = E + P + N, for all T.Before moving on to presenting the results of this paper, we observe briefly that under the assumption that the EGFR and PDGFRA amplified sub-populations do not interact with one another, i.e., L = 200 mm. Since we are only interested in running simulations to a biologically relevant size . Recall that the introduction times depend on the size of the non-amplified tumour population (N), through ρ, rather than introduce these populations at a specified point in time, we introduce them after a given number of proliferation events have occurred, i.e., a specified stage in the evolution of the tumours. In this case we introduce the amplified populations after the tumour has grown to six times its initial size, that is NE = NP = 6NI, where N population has grown to 11NI, we do not see them growing to detectable levels in our simulations.We begin by assuming that amplification of the EGFR or PDGFRA gene does not result in either sub-population, psy data  is the mPI model ), we usear as in . We alsoIn order to test whether neutral, competitive or cooperative interactions between EGFR and PDGFRA amplified sub-populations best describe the patterns observed in the biopsy data, we run numerical simulations of the model described in T = E + P+ N, above the 0.8K threshold is 36.2 mm and use this as a proxy for the size of a tumour at the time of diagnosis.We choose a biologically relevant size to represent a typical size of a GBM tumour at the time of diagnosis, shortly after which patients will usually undergo surgery to remove as much of the tumour as feasible, with biopsy samples being collected at this time. One way to measure the typical size of a GBM at diagnosis is to segment the tumour volume visible on a T1-weighted MRI with gadolinium contrast (T1Gd MRI), a type of scan that shows the most dense area of the tumour and is typically used in the process of diagnosing a patient with a GBM. From this, the diameter of the volume-equivalent sphere can then be computed and used as a measure to indicate the size of the tumour lesion, with the average diameter at diagnosis being 36.2 mm in unpublished data. Following Swanson et al. , we relaAE, is calculated asH(·) is the Heaviside step function. The proportions with neither gene, only the PDGFRA gene and both genes amplified, AN(t), AP(t) and AB(t), are defined and calculated in a similar way. We illustrate this schematically in We then run the numerical simulations until they reach this biologically relevant size with the parameter sets described above. Since the patient data is for the proportions of biopsies containing EGFR and PDGFRA amplified cells above a given density threshold, which we chose to be 10% of the tissue sample, we define an equivalent measure for each simulated tumour by integrating solutions across the whole tissue domain. For example, the proportion of the tumour with only EGFR amplified, ρ and D pairs with the different cases of competition, cooperation and neutralism are shown in E and P have the same proliferation and invasion parameters (ρ and D) and are both introduced at the same time and place and, thus, are effectively the same so we expect to see them together .The mean proportions from the simulations run using each of the four ρE, ρP, DE or DP); by changing the phylogenetic ordering of mutations (changing αEP or αPE); or, finally, by changing any combination of these factors.Clearly, the patterns of neither, only EGFR, only PDGFRA and both amplified proportions we see in these simulations do not reflect the patterns of amplification we see in the biopsy data in 3.3.1.ρE, ρP, DE and DP.The amplification of EGFR and PDGFRA genes are often considered to be among the key mutations driving oncogenesis and tumour growth , 22. SinAs we see a much higher proportion of biopsies with only EGFR amplified in the patient data , this co3.3.2.phylogenetic ordering, of mutations may be affecting the proportions of EGFR and PDGFRA amplified biopsies across the patient cohort  and PDGFRA (P) amplified populations are introduced, i.e., N) had grown to six times its initial size, 6NI, and so we now choose to investigate the patterns of gene amplification we see when the E and P populations are introduced earlier and later than this. Thus, we define a vector of possible introduction times, N population has reached a size of (i + 2)NI, for i = 1, …, 7. Implementing our model with Therefore, we assume once more that all cell sub-populations have the same proliferation and invasion parameters, i.e., P are introduced at E population is introduced at each of the seven possible times given by the vector t*. The points on the graph where E cells are introduced later than P cells, we see the proportions changing as we would expect, with the only PDGFRA amplified proportion increasing. We also note the slight decrease in the proportion of neither amplified cells when the EGFR amplified population is introduced at 3.3.3.Another factor that could result in some biopsies having only EGFR and others only PDGFRA amplified is that the mutations occurred in different places, resulting in the populations occupying different, spatially separated regions of the tumour. In all previous simulations presented in this paper we assumed that the mutation events leading to the establishment of EGFR and PDGFRA amplified sup-populations in our model occurred in the center of the growing tumour; this was a reasonable place to explore the effects of selection advantages and timing of mutations from, since it is where most proliferation is taking place in our model in the early phases of tumour growth and, therefore, where we may expect more mutations to appear. However, cells at the centre of the tumour also experience more competition for space, a growth limiting resource in our model, as this is where the highest tumour cell density is in these early growth phases. Therefore, we now explore the effects of introducing the EGFR and PDGFRA amplified sub-populations away from the centre of the tumour where there is less competition for space.N population is only six times its initial size), with the bulk of the tumour being contained within a width of 3mm for each  pair at this time. Thus we choose introduction locations no further than 1.5mm from the tumour centre as mutations are unlikely to occur beyond this point where concentrations of tumour cells are very low and, consequently, few proliferation events are occurring. We define a vector of possible introduction locations, x*. We show two simulation results in We use the same parameters and assumptions described in 3.4.To consider the implications of our model in a more comprehensive manner, in this section we conduct a sensitivity analysis through Latin Hyper-cube Sampling (LHS) and Partial Rank Correlation Coefficients (PRCC). This enables a better understanding of the effects of parameter values on the amplification patterns we observe across our model simulations. In our analysis we include 12 model parameters and assign a uniform probability density function (pdf) to each, with minimum and maximum values chosen in line with the ranges explored in previous sections of this paper; the details of which are outlined below and summarised in E and P populations over the N population, with minimum and maximum values of 1 and 1.5, i.e., no advantage and a 50% proliferation advantage. Similarly, we investigate the sensitivity of the model to invasive advantages afforded to the amplified sub-populations via the parameters NE or NP, of the growing tumour, which we also include in the sensitivity analysis with minimum and maximum values of 3NI and 9NI, where NI is size of the initial population of non-amplified tumour cells.In ρN, and diffusion coefficient, DN, of the non-amplified population of tumour cells (N) in our sensitivity analysis. As detailed in ρN, DN) pairs to represent the heterogeneity of tumours present in our patient cohort and calculated the average proportions from these four simulations, while other parameters in the model were varied. Therefore, we assign each parameter uniform pdfs with minimum and maximum values of 3 and 30, with appropriate units, to represent tumours with varying degrees of proliferative and invasive capabilities.In addition to these parameters, we include the introduction locations of the mutated populations, αPE and αEP, are the final parameters to be included in the sensitivity analysis. We note that we previously made the assumption that the interactions between the EGFR and PDGFRA amplified sub-populations were symmetric, that is α = αPE = αEP. This assumption allowed us to reduce the number of parameters in our model and study the amplification patterns for the three key cases of competition (α = −5), cooperation (α = 5) and neutralism (α = 0) throughout αPE and αEP to take different values and sample them independently from uniform distributions with minima and maxima of −5 and 5.The interactions, https://github.com/scmassey/model-sensitivity-analysis along with further details of the LHS-PRCC method.Briefly, the first step of the sensitivity analysis is to conduct the LHS for which we choose a sample size of 2000; each of the 12 parameter distributions given in The results from the LHS-PRCC sensitivity analysis for the four outputs of interest from our model, given by ρN and DN. This may be due to the effects at the edges of the simulated tumours, where the total tumour cell population, T = N + E + P, is above the threshold of detection and the amplified populations, E and P, remain undetected below the threshold (as illustrated in ρN decreases and DN increases, the profile of the tumour edges becomes flatter and this area at the edge of the tumour becomes wider, thus contributing more to the proportion of the simulated tumour with neither gene amplified. This suggests that to represent amplification patterns for a population of heterogeneous GBMs it is important to incorporate this heterogeneity into our mathematical modelling by considering a range of ρN and DN values, as we did throughout In αPE and αEP, have a strong impact on the proportion of simulations with both genes amplified; this is, again, consistent with our previous observations in αPE and αEP have opposite signs, say αPE > 0 and αEP < 0, then the EGFR amplified population will benefit, while the proportion with only PDGFRA amplified will decrease. The case where both parameters have the same sign is more difficult to understand due to the competing effects; a positive αPE will increase the only EGFR Amp proportion and have a stronger negative effect on the only PDGFRA Amp proportion, whereas a positive αEP, will have the opposite effect. Since the negative effects are stronger in this case, it is likely that the proportions with only one gene amplified will decrease, as the proportion with both amplified will increase when both interaction parameters are positive. Meanwhile, if αPE and αEP are both negative, the proportion with both genes amplified will decrease, as the EGFR and PDGFRA amplified sub-populations compete with one another; this is likely to result in each amplified population occupying distinct regions of the tumour or one population dominating, depending on the strength of the competitive interactions and various other factors, such as one population being introduced and becoming established before the other.In Finally, we note that the PRCC values between the introduction locations and each of the four outputs of interest are close to zero, indicating that they are not strongly correlated. While this may be expected, since our results in 4.in silico investigation into the levels of EGFR and PDGFRA amplified sub-populations observed under competitive, cooperative and neutral interactions between these cell types and compared our results to population levels of amplification observed in image-localized biopsy data from a cohort of GBM patients, where a high proportion of biopsies had only the EGFR gene amplified, a smaller proportion had both or neither gene amplified and very few showed amplification of only the PDGFRA gene (see In this paper, we have presented a novel mathematical model of the co-evolution of three distinct tumour cell sub-populations to investigate the nature of interactions between cells with two common mutations occurring in GBMs, namely amplification of the genes encoding the EGFR and PDGFRA proteins. We have used a PDE-based formalism, which reduces to the well known PI model –32 if wegene see .In carrying out computational simulations, we found that the amplification patterns observed in simulated tumours under each of the different interaction assumptions did not match those observed across the patient biopsy data when we assumed that cells with the EGFR and PDGFRA genes amplified did not differ in their dynamics, shown in in silico modelling approach has allowed us to investigate how different interaction assumptions influence the amplification patterns in simulated tumours and explore the effects of changing the parameters and the timing and position of sub-population introductions in our model; we found that some of these changes improved our simulation results with respect to the biopsy data and were also consistent with suggestions about EGFR amplified sub-populations found in the literature.Although the simulation results presented in this paper do not perfectly match the patterns of EGFR and PDGFRA amplification observed across the patient biopsy data, our In αPE and αEP to take different values. We found that, if they have opposite signs, one amplified population will benefit while the other decreases and that if they have the same sign but are not equal the results are more difficult to interpret due to competing effects. The effect of this on the amplification patterns observed across a cohort of tumours requires further investigation, which is something we plan to study in future work.Throughout our investigation in We also note that in this work we have avoided modelling single cell events in a macroscopic setting, by assuming that each of the EGFR and PDGFRA amplified sub-populations only become established within a tumour at most once and introduce a small distribution of cells accordingly. It is possible, however, that multiple mutation events resulting in EGFR and PDGFRA amplification in cells could be occurring in an evolving tumour and it may be more appropriate to model such single cell events in a micro- or meso-scopic setting. However, since we are interested in population level patterns of amplification and are working with large numbers of cells, this would be computationally expensive. In order to better capture single cell events while avoiding a large computational burden, it may be appropriate to consider a hybrid-modelling approach, similar to that described by Smith and Yates . Though in silico investigation in this paper. To be able to untangle the influence from and the nature of interactions from the effects of these other factors, more data may be required. In this study, we had biopsy data for a cohort of 25 patients and a larger number may enable us to gain more insight into the pattern of EGFR and PDGFRA amplification. Furthermore, data at multiple time points, such as biopsies sampled from primary and recurrent tumours, would enable us to extract more dynamic information about the co-evolution of these genetically-distinct sub-populations; this presents challenges, however, as treatment effects would also have to be taken into account. Alternatively, a combination of single- and mixed-cell cultures and mathematical modelling may be able to identify the nature of interactions in vitro and provide some useful insights into the co-evolution of EGFR and PDGFRA sub-populations in vivo if such data were to become available.Determining the nature of interactions between EGFR and PDGFRA amplified sub-populations in GBMs is a complex biological problem, with factors relating to selection advantages and the phylogeny of these tumours influencing the balance of populations we see in a tumour, as we have demonstrated with our 1


However, the effects of local CO2 administration on tumour immunosuppression, chemoresistance, and combination with chemotherapy are unknown. In this study, we investigated the effects of local CO2 administration on squamous cell carcinoma and the effects of combined use with chemotherapy, focusing on the effects on tumour immunosuppressive factors.  In recent years, the tumour immunosuppressive mechanism has attracted attention as a cause of tumour chemoresistance. Although chemoresistance and immunosuppression of tumours have been reported to be associated with a hypoxic environment, effective treatments to improve hypoxia in tumours have not yet been established. We have previously applied carbon dioxide  was evaluated using real-time polymerase chain reaction and immunostaining.  Human oral squamous cell carcinoma (HSC-3) was transplanted subcutaneously into the back of a nude mouse, and CO2-treated and combination groups. Similarly, the expression of PD-L2 and galectin-9 decreased in the CO2-treated and combination groups. Furthermore, immunostaining also showed a significant decrease in the protein expression of tumour immunosuppressive factors in the CO2-treated and combination groups.  Compared with the control group, a significant decrease in the mRNA expression of PD-L1 was observed in both, CO2 administration to the mouse model. CO2 administration has the potential to improve the hypoxic environment in tumours, and combined use with chemotherapy may also improve tumour immunosuppression. It was confirmed that the tumour immunosuppressive factors decreased due to local CO The currently available main standard treatments for head and neck cancers are surgery, radiotherapy, and chemotherapy. Among them, chemotherapy is often selected in combination with radiotherapy as either radical or additional postoperative treatment. In addition, chemotherapy is often used to treat recurrent and metastatic cancer. However, resistance to chemotherapy is an important problem in cancer treatment.Hypoxia is one of the most important factors that cause chemotherapy resistance. For head and neck squamous cell carcinoma (HNSCC), hypoxia-induced drug resistance has been reported with cisplatin administration , 2. One In recent years, tumour immunosuppression, in which cancer avoids the immune system of the living body, has received attention as a cause of cancer treatment resistance. Tumour immunosuppression is also related to hypoxia –10. A hy2) therapy is generally known for improving the hypoxic environment. This effect of CO2 is mainly caused by an increase in blood flow and a partial increase of O2 pressure in the local tissue; this is known as the Bohr effect [2 administration method, which can allow efficient local absorption of CO2 [2-absorbing hydrogel allows absorption of CO2 gas through the skin, and the pH of the solution decreases depending on the volume of absorbed CO2 (H2O + CO2⟶H+ + HCO3−). A study using near-infrared spectroscopy demonstrated that this transcutaneous application of CO2 upregulates O2 pressure in the local tissue [2 to SCC in vivo and discovered that it improved local oxygenation in the tumour [2 administration on tumour immunosuppression and chemoresistance, when used alone and in combination with chemotherapy, are unknown. We hypothesised that improving the hypoxic environment by CO2 administration would decrease immunosuppressive factors such as PD-L1, PD-L2, and galectin-9 and improve chemoresistance.Carbon dioxide . It was established from a metastatic deposit of poorly differentiated SCC of the tongue in a midinternal jugular lymph node from a 64-year-old man . HSC-3 c6 cells in 300 mL Eagle's minimum essential medium) were injected subcutaneously into the dorsal region of the mice.Male athymic BALB/cAJcl-nu/nu nude mice aged 7 weeks were obtained from CLEA Japan . The animal experiments were approved by the Institutional Animal Care and Use Committee (Permission number: P-170402) and were performed in accordance with the Guidelines for Animal Experimentation at Kobe University Animal Experimentation Regulations. HSC-3 cells (4 × 102absorption-enhancing hydrogel (CO2 hydrogel), and this area was then sealed with a polyethylene bag; 100% CO2 gas was then pumped into the bag [2 treatment was applied for 20 min, following which the hydrogel was gently wiped off the skin. Control animals were treated similarly, with room air replacing the CO2 [As previously described, the area of skin around the implanted tumour was covered with a CO the bag   was injected intraperitoneally at a dose of 4 mg/kg twice a week for 2 weeks , 24.n = 10), a CO2-treated group (n = 10), a CDDP-treated group (n = 10), and a CO2 and CDDP combination-treated (combination) group (n = 10). Treatment commenced 14 days after HSC-3 cell implantation and was performed twice a week for 2 weeks. Tumour volume and body weight were monitored twice weekly until the end of treatment; tumour volume was calculated according to the formula V = π/6 × a2 × b, where a and b represent the shorter and longer diameters of the tumour, as previously described [Forty mice were randomly divided into four groups: a control group  and reverse (5′-CAC CTT CAC CGT TCC AGT TT-3′), which was purchased from Invitrogen  [β-actin, PD-L1, PD-L2, and galectin-9 was analysed using quantitative real-time polymerase chain reaction (PCR). Total RNA was extracted from the samples using 500 μL of the TRIzol reagent (Invitrogen) per 10 mg of thinly sliced tissue and cleaned using an RNeasy Mini Kit . cDNA was synthesised  using a High-Capacity cDNA Reverse Transcription Kit . mRNA expression was analysed by quantitative real-time PCR. Quantification of mRNA transcription was performed using an Applied Biosystems StepOne Real-Time PCR System (Applied Biosystems). Reaction conditions included 95°C for 10 min, followed by 40 cycles at 95°C for 15 s and at 60°C for 1 min. The level of each target gene was normalised to the β-actin level and expressed relative to the levels of the control group  [Primers for CA, USA) . Primerssystems) .2O2, and incubated overnight at 4°C with the following primary antibodies in Can Get Signal Immunostain Solution A : PD-L1 polyclonal antibody (Invitrogen), PD-L2 polyclonal antibody (Invitrogen), and galectin-9 polyclonal antibody (Invitrogen). Following this, sections were incubated with horseradish peroxidase- (HRP-) conjugated goat anti-rabbit IgG polyclonal antibody  for 30 min at room temperature. Signals were developed as a brown reaction product using peroxidase substrate 3,3′-diaminobenzidine (Nichirei Bioscience). The sections were counterstained with haematoxylin and examined under a BZ-8000 confocal microscope . Immunohistochemical staining was quantified using Hybrid cell count BZ-H3C software (Keyence) [For immunohistochemical staining, formalin-fixed and paraffin-embedded tumour sections were pretreated with pH 9 Tris/EDTA buffer for 40 min at 95°C, quenched with 0.05% HKeyence) .p < 0.05.Data are presented as the mean ± standard error. The results were analysed using Kruskal-Wallis and Steel-Dwass tests; the level of statistical significance was set at 2-treated group after the intervention (In the CDDP-treated and combination groups, the body weight of the mice at the end of the intervention was significantly reduced compared to that in the control group. In contrast, no significant change in body weight was observed in the COrvention .2-treated, CDDP-treated, and combination groups, compared to the control group. The combination group demonstrated the smallest increase in tumour volume (After 14 days, we found a significant decrease in tumour volume in the COr volume .2-treated and combination groups than in the control group. Similarly, PD-L2 and galectin-9 expression in the CO2-treated and combination groups tended to be lower than those of the control and CDDP-treated groups. However, the difference in PD-L2 expression in each group was not statistically significant (Quantitative real-time PCR showed that the mRNA expression of PD-L1 was significantly lower in the COnificant .2-treated and combination groups compared to the control and CDDP-treated groups (Figures Consistent with the results of quantitative real-time PCR, immunohistochemical analysis revealed significantly decreased expression levels of PD-L1, PD-L2, and galectin-9 in the CO Figures  and 6.2 application reduced the expression of PD-L1, PD-L2, and galectin-9 in SCC tissues. The combination of cisplatin and CO2 application also reduced the expression of these tumour immunosuppressive factors.In this study, we showed that transcutaneous CO2 administration on chemotherapy and tumour immunosuppression. The negative impact of hypoxia on cancer cells in relation to the efficacy of chemotherapy has been known for several decades [To the best of our knowledge, this is the first study on the effects of local CO decades . As tumo decades . Further decades .In recent years, immune checkpoint inhibitors have been shown to affect cancers that are resistant to conventional chemotherapy, and the involvement of tumour immunosuppression in cisplatin-resistant tumours has attracted attention . The PD-2 administration does not increase the toxicity of cisplatin.In contrast, there are various reports on the effects of cisplatin and tumour immunosuppressive factors. Many studies have shown that PD-L1 and PD-L2 are upregulated by chemotherapy including cisplatin, but some have shown contrasting results. Ock et al. reported that HNSCC cell lines treated with cisplatin show increased PD-L1 expression . There aα, a transcription factor that promotes the transcription of genes required for adaptation to hypoxia, regulates PD-L1 expression transcriptionally [Hypoxia can affect immune evasion in tumours, and several mechanisms have been reported . HIF-1α,tionally , 12. It tionally . It has tionally . These ftionally . Howevertionally .2 improves hypoxia in healthy people and various animal models [2 application to the flap on the back of rats improves its blood flow and reduces HIF-1α [2 application also suppresses the growth of primary human SCC and related lymphogeneous metastasis by making their environment less hypoxic and increasing HIF-1α [2-treated group was caused by the improvement of hypoxia through CO2 application. In the combination group, galectin-9 showed similar results as those of PD-L1 and PD-L2. Although the effect of the combined use with cisplatin could not be confirmed at this time, the findings suggest that CO2 application is effective in reducing tumour immunosuppressive factors that are generally elevated. Based on the findings of this study, we speculate that the combined administration of CO2 may reduce chemoresistance to cisplatin by improving hypoxia.We have previously reported that the transcutaneous application of COl models , 43, 44.s HIF-1α . Transcug HIF-1α , 17. In 2 administration method used in this study lie in the fact that it is an inexpensive and simple method, which can efficiently supply oxygen locally. If transcutaneous CO2 administration can improve tumour immunosuppression and treatment resistance, it is expected to have many subsequent effects, such as improvement of patient prognosis, increase in survival rate, decrease in drug dose, and reduction of side effects associated with tumour treatment. However, for clinical application, gaseous CO2 cannot be applied to the head and neck region; this is a limitation. We are therefore developing a paste, in which CO2 is generated; the produced CO2 is efficiently absorbed from the skin without the formation of gaseous CO2.The strengths of the transcutaneous CO2 application to a mouse model, in which an SCC was transplanted, reduced tumour immunosuppressive factors such as PD-L1, PD-L2, and galectin-9. This suggests that transcutaneous CO2 application improved the hypoxic environment in the tumour and that combined use with chemotherapy may also improve the tumour immunosuppressive mechanism. Further studies are required to confirm the mechanism and clinical effect of CO2 application on immunosuppression and chemotherapy.We confirmed that transcutaneous CO


In the original publication , there wIncorrect fundingThis work was supported by the National Natural Science Foundation of China (Grant Number: 81873538) and Key Scientific Research Projects of Colleges and Universities in Henan Province (Grant Number: 20A320033).Correct fundingThis work was supported by the National Natural Science Foundation of China  and Key Scientific Research Projects of Colleges and Universities in Henan Province (Grant Number: 20A320033).